The Updates on COVID Testing with Ask. Dr. Melinda Ep. 131 - a podcast by IQ Podcasts

Charles Strongo has 30 years’ experience in business management and operations. Mr. Strongo has been in the in vitro diagnostic business for the past twenty-Four years, since 1995, the beginning of the “over-the-counter” in-vitro diagnostic industry and has managed annual budgets exceeding $500 million.

Mr. Strongo is the CEO and Chairman of WholeHealth Products Inc. from 2013 to present. Mr. Strongo also currently serves as CEO of Nunzia Pharmaceutical Company (“Nunzia”) since August 1, 2019. Nunzia owns the rights to a drug that treats autism, fragile X, ADHD, and PTSD and intends to manufacture, market, and distribute the drug Nunzia, once approved by the FDA through a Premarket Approval.

Mr. Strongo has served as President and Chief Executive Officer of EarlyDETECT, Inc. from March 2004 through November 2009. He was a member of the EDI Board of Directors from June 2002 until June 2009. Prior to that, Mr. Strongo served as the Chief Financial Officer for two years.

Mr. Strongo has owned and operated his own successful FDA Approved diagnostic manufacturing facility. Mr. Strongo has a comprehensive knowledge of ISO and FDA regulations and has prepared several companies for the ISO inspections. Mr. Strongo has filed more than twenty FDA 510K filings; he has also worked on countless pharmaceutical filings. Mr. Strongo has prepared several companies for FDA inspections, under FDA regulatory GMP guidelines. Mr. Strongo has cleared companies for ISO 13485 CDM in less than 6 months, a process that usually takes a year.

Mr. Strongo’s dynamic personality, keen understanding, and extensive professional expertise, have enabled Mr. Strongo to increase profitability for multiple companies domestically and internationally. Mr. Strongo established businesses in foreign countries, including Canada, Brazil, China, South Africa, Russia, Taiwan, Mexico, Malaysia, Thailand, and the Philippines. Mr. Strongo holds a BA/MBA in Business Management from National University.

David has worked in the In-Vitro Diagnostic business for the last 2 years, working with both Nunzia Pharmaceutical and Global Whole Health Partners Corp. David brings a youthful outlook and a modern vision to the industries. David is outgoing and friendly, but with enough knowledge to be able, to explain both types of products from both companies. Nunzia Pharmaceutical Corp (Trading Symbol NUNZ), with its Pharmaceutical and Nutraceutical Products to help those with ASD (Autistic Spectrum of Disorders) and Compulsive Disorders,​ is growing and David is a valuable part of the growth of the company. Global WholeHealth Partners Corp, (Trading Symbol GWHP) with its more than 100 types of test is growing exponentially due to the CoViD19 tests and David has diligently worked hard on sales and has used his demeanor with great success.
gwhpcorp.com
Presented by Attorney King Studios with Ask Dr. Melinda on IQ Podcasts.

Further episodes of IQ PODCASTS

Further podcasts by IQ Podcasts

Website of IQ Podcasts